NextGen Sciences Launches CNS Disease Biomarker Assay

NextGen Sciences aims to be a leader in the growing CNS biomarker market, launching a new tool to help researchers identify disease biomarkers. Their new multiplex panel consists of 82 human proteins found in the cerebrospinal fluid that may have potential to diagnose ALS, Parkinson’s and other neurodegenerative diseases. Power3 Medical Products has a similar product in development based on serum markers (read here: http://www.marketwatch.com/story/amarantus-biosciences-licenses-parkinsons-disease-diagnostic-biomarker-test-from-power3-medical-products-2012-01-23).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail